Get regular updates to your inbox.
A global Phase 4 clinical trial of Enspryng (satralizumab), approved to treat the most common form of neuromyelitis optica spectrum disorder (NMOSD), is enrolling newly diagnosed and other patients who could not or did not take part in Phase 3 trials of the therapy. In addition to people new…
More than a third of people with neuromyelitis optica spectrum disorder (NMOSD) show cognitive impairment, particularly in visual processing speed and verbal domains, according to a large study in Germany. This cognitive impairment was independent of disease duration and remained constant over two years of follow-up. It also did…
People with neuromyelitis optica spectrum disorder (NMOSD) have a significantly higher neutrophil-to-lymphocyte ratio (NLR), an immune cell-based marker of inflammation, than healthy people, a review study showed. A higher NLR ratio was also significantly associated with a greater chance of relapse, severe disability, and new or enlarging lesions on…
Access to care and the use of healthcare services during the COVID-19 pandemic were generally kept up in people affiliated with specialized centers in Germany and Austria who had neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD), a study showed. Moreover, “patients’ satisfaction with medical…
Get regular updates to your inbox.